葡萄糖类-1受体激动剂和肌肉质量影响
Alexandr Ceasovschih1, Andreea Asaftei1, Maria Giovanna Lupo2
1Faculty of Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, Iasi, Romania; 2nd Internal Medicine Clinic, 'Sf. Spiridon' Clinical Emergency Hospital, Iasi, Romania.
Pharmacological research
|August 26, 2025
概括
葡萄糖类-1受体激活剂 (GLP-1RA) 有效治疗肥胖症,但可能会减少肌肉质量. 在GLP-1 RA治疗期间需要采取策略来保持肌肉健康.
科学领域:
- 内分泌学
- 代谢疾病
- 老年病学
背景情况:
- 葡萄糖类-1受体激动剂 (GLP- 1 RAs) 在治疗肥胖方面非常有效.
- 新出现的证据表明GLP-1RA可能会对骨肌肉产生负面影响.
研究的目的:
- 审查GLP-1RA对人体构成的影响.
- 探索GLP-1引起的肌肉衰竭的机制.
- 提出减轻肌肉损失的策略.
主要方法:
- 临床和准临床研究的文献综述.
- 对病理生理机制的分析.
- 综合基于证据的管理策略.
主要成果:
- GLP-1RA显示显著的体重减轻和新陈代谢改善.
- 观察到可能导致骨肌肉量意外减少.
- 在老年或脆弱的个体中风险更高.
结论:
- 在治疗肥胖症方面,GLP-1RA是至关重要的.
- 保持肌肉质量对于功能状态和生活质量至关重要.
- 早期识别和管理风险是优化GLP-1 RA治疗的关键.
相关概念视频
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Hormones Regulating Blood Glucose
4.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.0K
Hypoglycemia and Glucagon
334
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
334
cAMP-dependent Protein Kinase Pathways
6.6K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.6K
GPCRs Regulate Adenylyl Cylase Activity
5.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.9K
Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256


